Search PubMed⌕ Search

Biomedical subjects

S Matsuda

Publications and source records attributed to S Matsuda.

At least 595 records · Page 33Linked to original sources
PubMed1986

Long-term results and its managements after coronary bypass surgery.

Between 1970 and 1985, 221 patients with coronary artery occlusive disease underwent aorto-coronary bypass (A-C bypass) and other procedures. Among these patients, 187 had A-C bypass alone and A-C bypass in addition to correction of valvular lesions or arterialization of the coronary vein, myocardial puncture by laser. The remaining 34 had surgical corrections for myocardial infarction and its complications. Subjects were 100 patients who underwent A-C bypass alone over 6 months ago and whose follow-up study could be performed in 93 survival cases [corrected]. Subsequently, 94% of the patients have met the criteria for grade I of NYHA functional capacity and have returned to normal work at a mean of 4 years and 2 months after surgery. Improved left ventricular function has been maintained postoperatively in the patients with complete revascularization. Improved operative technique, in addition to intraoperative balloon angioplasty and onlay patch grafting, have increased the patency rate (78% in 1 mm, 94% in 2 mm of coronary diameter) of the grafts with postoperative anticoagulant therapy. On the basis of our long-term observations, coronary bypass surgery, particularly in complete revascularization, provides for significant improvement in both the quality and life expectancy of patients with severe coronary heart disease. Treadmill exercise test and magnetic resonance image (MRI) were useful, non-invasive and acceptable examinations in long-term follow up.

Angina Pectoris↗
PubMed1986

Ultrastructure of erythrocytic stages of Plasmodium ovale in humans.

An electron microscopic study of Plasmodium ovale in humans supplied information on the fine structure of erythrocytic trophozoites, presegmenting schizonts and gametocytes. Ultrastructural features of P. ovale appeared quite similar to those described in other mammalian malarial parasites. However, some minor structural variations were observed. The parasite was a fairly compact cell of an oval shape. However, occasionally trophozoites had slender cytoplasmic protrusions. Ingestion of host cell cytoplasm occurred cytostomally. Nucleus contained a nucleolus-like dense region. The asexual parasites possessed acristate mitochrondria and were surrounded by a single-membraned pellicle in addition to a parasitophorous vacuole membrane. The gametocytes, however, possessed cristate mitochondria and were surrounded by a three-membraned pellicle in addition to a parasitophorous vacuole membrane.

Adult↗
PubMed1986

Ultrastructure of human erythrocytes infected with Plasmodium ovale.

Ultrastructural changes of the human erythrocytes infected with Plasmodium ovale were studied, and differences of P. ovale from other human malarial parasites were discussed. Four characteristic morphological alterations were observed on the host cells: caveola-vesicle complex, excrescence, nodule, and cytoplasmic cleft. Caveola-vesicle complexes consisted of caveolae surrounded by vesicles in an alveolar fashion and were formed along the host cell plasmalemma. Similar complexes have been reported previously in P. vivax but not in P. falciparum and P. malariae. This complex probably corresponds to a Schüffner's dot. Excrescences similar to those observed by others on the host cell membrane in P. falciparum and P. malariae were observed also in P. ovale. The excrescences in P. ovale, as in P. falciparum, were limited to the erythrocytes infected by asexual parasites, whereas the excrescences in P. malariae have been demonstrated on erythrocytes with asexual parasites and gametocytes. Nodules were observed on the erythrocytes infected with asexual parasites of P. ovale. Structures such as the nodule have not been described previously in the erythrocytes infected with any other species of malarial parasite. Clefts within the cytoplasm of the host erythrocytes were present in P. ovale, as in all other malarial parasites.

Adult↗
PubMed1986

Medical treatment for inoperable insulinoma: clinical usefulness of diphenylhydantoin and diltiazem.

This report describes a 78-year-old woman with insulinoma, treated with a combination of diphenylhydantoin and a calcium antagonist. The effectiveness of 200 mg of diphenylhydantoin and 180 mg of diltiazem was evaluated by measuring the levels of plasma glucose, immunoreactive insulin and immunoreactive insulin/plasma glucose after fasting or by the oral glucose tolerance test, and by the appearance of hypoglycemic symptoms. The mean concentration of fasting plasma glucose increased significantly during the treatment. The levels of immunoreactive insulin/plasma glucose and C-peptide immunoreactivity/plasma glucose significantly decreased. Symptomatically, no episode of hypoglycemia was noted during the combined treatment.

Adenoma, Islet Cell↗
PubMed1986

[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology. Study group of imipenem/cilastatin sodium in the field of obstetric and gynecological infections].

Fundamental and clinical studies were performed by our study group to evaluate the usefulness of the combination (1:1) of imipenem (MK-0787), a carbapenem antibiotic, and cilastatin sodium (MK-0791), an inhibitor of dehydropeptidase-I, in the treatment of patients with obstetric and gynecologic infections. The following results were obtained. Antimicrobial activities of MK-0787 were tested with inocula of 10(6) cells/ml of organisms isolated from patients with obstetric and gynecologic infections. Peak MIC's of MK-0787 were less than or equal to 0.20 micrograms/ml for S. aureus, less than or equal to 0.20 micrograms/ml for S. epidermidis, 1.56 micrograms/ml for E. faecalis, 0.39 micrograms/ml for E. coli, less than or equal to 0.20 micrograms/ml for K. pneumoniae and less than or equal to 0.20 micrograms/ml for B. fragilis. When 0.5 g/0.5 g of MK-0787/MK-0791 was administered by a 30-minute intravenous drip infusion, maximum concentrations of MK-0787 in all female genital tissues were obtained at the end of the infusion, and Cmax ranged from 9.4 micrograms/g to 17.0 micrograms/g. In addition, the maximum concentration of MK-0787 in pelvic dead space exudate was 13.2 micrograms/ml at 88 minutes after the start of the infusion. The penetration of MK-0787/MK-0791 into female genital tissues and dead space exudate was found to be good and sufficient to cover MIC's against organisms isolated from patients with obstetric and gynecologic infections. Clinical efficacy was evaluated in 201 evaluable patients out of a total of 253 patients with obstetric and gynecologic infections. Clinical responses were excellent in 2, good in 181 and poor in 18 patients, and the efficacy rating was 91.0 percent. Efficacy ratings classified by types of infections were 93.2% (82/88) for intrauterine infections, 83.0% (39/47) for intrapelvic infections, 100% (26/26) for adnexitis, 90.0% (18/20) for infections of the external genital organs and 90.0% (18/20) for other infections. Side effects were observed in 6 of the 253 patients; rash in 4, nausea and vomiting in 1 and diarrhea in 1 patient. Abnormal laboratory findings were observed in 10 of the 253 patients; elevation of GOT, GPT, LDH and Al-P in 1, elevation of GOT, GPT and Al-P in 1, elevation of GOT and GPT in 4, elevation of GPT in 1, elevation of BUN in 1, increase of eosinophiles in 1, decrease of segmented neutrophils in 1 patient.

Adult↗
PubMed1986

[Clinical and laboratory evaluations of ceftazidime in perinatal use. A study of ceftazidime in the perinatal co-research group].

Efficacy and safety of ceftazidime (CAZ) in women during the perinatal period and their neonates were evaluated by a perinatal co-research group, and the results obtained were summarized as follows. Following an intravenous bolus injection or a drip infusion of CAZ from 1 g to 2 g, CAZ was transferred to maternal serum, umbilical cord serum and amniotic fluid rapidly and effectively. In 31 cases of perinatal infections, clinical efficacy was excellent in 10 cases, good in 18 and poor in 3, with an efficacy rate of 90.3%. In 85 cases given CAZ for prophylaxis of infections accompanying premature rupture of the membrane or following cesarean section, prophylactic effects were noted in 81 cases (efficacy rate: 95.3%). Neither adverse effects, nor abnormal laboratory findings were observed in any case. Also, no abnormalities in total serum bilirubin were observed in any neonates. From the above results, CAZ is considered to be a safe and useful drug for infections in women in perinatal period, usually in a unit dose of 1 g twice daily, or if necessary, 2 g twice daily.

Adult↗
PubMed1986

[Primary papillary adenocarcinoma of renal pelvis: a case report and review of the literature].

A rare case of primary papillary adenocarcinoma of the renal pelvis is reported. A 75-year-old man was introduced to our institute because of chance hematuria. He had no history of urolithiasis or urinary tract infection. Excretory urography showed a space taking lesion at the lower position of left renal pelvis with low function. Because of advanced stage with paraaortic lymphnode invasion, simple nephrectomy followed by irradiation and systemic chemotherapy with 5-FU was done. He died of pneumonia and acute heart failure after subtotal gastrectomy for peptic ulcer four months after the nephrectomy. Excised specimen revealed papillary adenocarcinoma of the renal pelvis without mucin production. This case was the 51st case reported in the literature. A short review of the disease is also reported.

Adenocarcinoma↗